662Cerebellar liponeurocytoma (LPN) is a rare central nervous system tumour recently recognized as a distinct clinicopathological entity. It was included in the previous 2000 edition of the World Health Organization (WHO) classification as a grade I neoplasm under the heading of glioneuronal tumours 1 . With increasing recognition of this entity and longer clinical follow-up periods in its investigation, it has become clear that this tumour has a rate of recurrence that is higher than previously thought and not compatible with a grade I designation. In light of the substantial rate of tumour recurrences, the current 2007 WHO classification assigns the cerebellar liponeurocytoma to WHO grade II tumour 2 . In this paper, we report a new case of a recurrent cerebellar LPN with supratentorial extension despite persistently benign histological features. To the best of our knowledge, recurrent cerebellar LPN with supratentorial extension has never been reported before, as the nine cases of recurrent cerebellar LPN published to date were confined to the posterior fossa. CLINICAL HISTORYA 42-year-old previously healthy man, presented with a fivemonth history of headaches, vertigo, visual disturbance and progressive unsteadiness of gait. On admission, neurological examination showed signs of cerebellar dysfunction, including ataxia, wide-based gait, right dysmetria on finger-to-nose testing and a positive Romberg sign. The fundus examination revealed unilateral papilloedema. Computed tomogram scan ( Figure 1) demonstrated a hypodense lesion within the vermis and right cerebellar hemisphere compressing the 4th ventricle and enhancing after contrast injection. Magnetic resonance imaging (MRI) scan showed a heterogeneous mass measuring 5 × 4 cm, characterized by discrete hyperintensity on T1-weighted images and high signal intensity on T2-weighted images. Several central parts of the lesion were very hyperintense on both T1 and T2-weighted sequences suggesting fat content. An intra-operative frozen section was reported as being consistent with a medulloblastoma. A gross total resection of the tumour was achieved. Histological examination of the surgical specimen revealed cerebellar tissue infiltrated by a highly cellular tumour formed by sheets of isomorphic small round cells (Figure 2). A significant proportion of the tumour demonstrated lipomatous differentiation characterized by large areas of cells containing a single cytoplasmic vacuole displacing the nucleus to the periphery mimicking mature fat cells (Figure 2A). There were only occasional mitotic figures and a low rate of proliferation Figure 2B) and neuron-specific enolase. Glial fibrillary acidic protein immunopositive tumour cells confirmed the presence of an additional glial component. All of these features were considered to be consistent with the diagnosis of cerebellar liponeurocytoma. A post-operative MRI performed three days after the surgery, demonstrated no residual tumour. No adjuvant radiation therapy was administered post-operatively. At the last rout...
Introduction: Central nervous system tumours represent 20% of all childhood cancers, and are the second most common group of neoplasms after leukaemias. Objective: To describe epidemiological characteristics of central nervous system tumours in a paediatric Tunisian population. Patients and Methods: A retrospective study of 492 childhood central nervous system tumours operated between 1990 and 2004 was undertaken. We investigated the age-related location, gender distribution and the histology of all tumours, and adopted the latest WHO classification (2007) in grouping all the tumours. Results: There were 488 primary and 4 secondary tumours; 426 (86.6%) were intracranial and 66 (13.4%) were intraspinal. Of the 426 intracranial tumours, 214 (50.24%) were supratentorial and 212 (49.76%) were infratentorial. The median age at diagnosis was 8 years, with a male:female ratio of 1.14:1. Low-grade tumours (WHO I/II) constituted 67.3% of all lesions and the rest (32.7%) were high-grade tumours (WHO III/IV). The most common tumour found in our series was astrocytoma (38%), followed by medulloblastoma (16.2%), then ependymoma (6.9%), cystic tumours (6.3%) and craniopharyngioma (5.3%). The overall 5-year survival rate was 45% with a mean follow-up period of 36 months. Conclusion: In our patient population, the incidence and distribution of central nervous system tumours were similar to those reported in literature. Overall survival rates varied according to tumour location and histopathology.
Hydatid cysts should be included in the differential diagnosis of unilateral proptosis in patients from regions where echinococcosis is endemic.
BackgroundLeiomyomas are benign tumors observed mainly in adult women. The retroperitoneum is a rare location for leiomyomas; almost 100 cases have been reported. Because retroperitoneal leiomyomas are paucisymptomatic and the tumor size at diagnosis is relatively large, surgical management is challenging. Regular follow-up is required because recurrence and malignant sarcomatous transformation have been described in a few cases.Case presentationWe report a case of a 52-year-old North African woman with a 22-cm retroperitoneal leiomyoma. A preoperative embolization was performed 2 days before surgery. The clinical, therapeutic, and evolutive aspects of this rare entity are discussed.ConclusionsDespite its benignity, retroperitoneal leiomyoma is a challenging diagnostic, therapeutic, and evolutive condition. Surgeons must consider mainly the tumor’s vascularization. Regular follow-up is mandatory because malignant transformation cannot be excluded.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.